Predicting outcome from post-transplant lymphoproliferative disease: A risky business

Pediatric Transplantation

Volumn 5, Issue 4, 2001, Pages 235-238

  Green, M ^a   Michaels, M ^a   Webber, S ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHILD; CYTOTOXIC T LYMPHOCYTE; EDITORIAL; EPSTEIN BARR VIRUS; HUMAN; IMMUNE DEFICIENCY; INCIDENCE; LYMPHOPROLIFERATIVE DISEASE; MORTALITY; ORGAN TRANSPLANTATION; OUTCOMES RESEARCH; PREDICTION; RISK FACTOR; SEROCONVERSION; VIRUS INFECTION;

BONE MARROW TRANSPLANTATION; CHILD; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOSUPPRESSION; INCIDENCE; LYMPHOPROLIFERATIVE DISORDERS; ORGAN TRANSPLANTATION; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TREATMENT OUTCOME;

EID: 0034940082     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3046.2001.005004235.x     Document Type: Editorial

References (15)

1. Posttransplant lymphoproliferative disease in children
2. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: Risk factors, treatment and outcome
3. The role of adoptive immunotherapy in the prevention and treatment of lymphoproliferative disease following transplantation
4. Adoptive immunotherapy for EBV lymphoproliferative diseases
5. Production of genetically modified Epstein-Barr virus specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease
6. Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy
7. Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression
8. Lymphoproliferative disorders after organ transplantation in children
9. The management of Epstein-Barr virus associated posttransplant lymphoproliferative disorders in pediatric solid-organ transplant recipients
10. Posttransplant lymphoproliferative disease in pediatric liver transplantation
11. Pretransplant assessment of the risk of lymphoproliferative disorder
12. Increased levels of circulating Epstein-Barr virus-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients
13. The role of viral load in the diagnosis, management and possible prevention of Epstein-Barr virus-associated posttransplant lymphoproliferative disease following solid organ transplantation
14. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders
15. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression